Sanofi SA vs Vanguard International High Dividend Yield ETF — how do they compare? Sanofi SA trades at $40.04 (market cap $95.18B), while Vanguard International High Dividend Yield ETF trades at $100.66 (market cap $22.80B). The key difference: Sanofi SA is far larger — about 4.2× Vanguard International High Dividend Yield ETF's market cap, and Sanofi SA pays a 6.01% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| SNY | VYMI | |
|---|---|---|
Market Cap | $95.18B | $22.80B |
Volume | 2,995,646 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $52.34 | $107.13 |
52-Week Low | $39.51 | $82.92 |
Typical Hold Time | 94 Days | 50 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
VYMI trades at $100.53 with a slight 0.3% daily gain, though technical indicators signal bearish momentum with moving averages showing 11 sell signals versus 2 buy signals. The ETF's recent performance includes a 29% one-year return and 14.13% five-year average annual return, with strong institutional interest as firms like Envestnet increased holdings by 22% in Q2 2026. A dividend of $0.82 is scheduled for payment on September 22, 2026.
The outlook for VYMI is mixed; bullish sentiment from Seeking Alpha highlights sector catalysts in financials, energy, and healthcare supporting dividend growth, while technical bearishness and Fed rate hike impacts pose risks. Investors may find value in its 3.61% dividend yield and global diversification, but should monitor financials exposure (43.6% of holdings) amid rising rates.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →